• 1
    Marrie TJ. Epidemiology of community-acquired pneumonia in the elderly. Semin Respir Inf 1990; 5: 260268.
  • 2
    Almirall J, Morato I, Riera F et al. Incidence of community-acquired pneumonia and Chlamydia pneumonia infection: a prospective multicenter study. Eur Respir J 1993; 6: 614618.
  • 3
    Lave JR, Fine MJ, Sankey SS et al. Hospitalized pneumonia. Outcomes, treatment patterns, and costs in urban and rural areas. J Gen Intern Med 1996; 11: 415421.
  • 4
    Woodhead MA, Macfarlane JT, McCracken JS et al. Prospective study of the aetiology and outcome of pneumonia in the community. Lancet 1987; i: 671674.
  • 5
    Guest JF, Morris A. Community-acquired pneumonia: the annual cost to the National Health Service in the United Kingdom. Eur Respir J 1997; 10: 15301534.
  • 6
    British Thoracic Society Research Committee and Public Health Laboratory Service. The aetiology, management and outcome of severe community-acquired pneumonia on the intensive care unit. Respir Med 1992; 86: 713.
  • 7
    Torres A, Serra-Batlles J, Ferrer A et al. Severe community-acquired pneumonia: epidemiology and prognostic factors. Am Rev Respir Dis 1991; 144: 312318.
  • 8
    Fine MJ, Smith MA, Carson CA et al. Prognosis and outcomes of patients with community-acquired pneumonia. A meta-analysis. JAMA 1996; 275: 134141.
  • 9
    Ramirez JA, Vargas S, Ritter GW et al. Early switch from intravenous to oral antibiotics and early hospital discharge: a prospective observational study of 200 consecutive patients with community-acquired pneumonia. Arch Int Med 1999; 159: 24492454.
  • 10
    Ramirez JA, Bordon J. Early switch from intravenous to oral antibiotics in hospitalized patients with bacteremic Streptococcus pneumoniae community-acquired pneumonia. Arch Int Med 2001; 161: 848850.
  • 11
    Ramirez JA. Switch therapy in adult patients with pneumonia. Clin Pulm Med 1995; 2: 327333.
  • 12
    Halm EA, Fine MJ, Marrie TJ et al. Time to clinical stability in patients hospitalized with community- acquired pneumonia: implications for practice guidelines. JAMA 1998; 279: 14521457.
  • 13
    Menéndez R, Torres A, Zalacain R et al. Risk factors of treatment failure in community-acquired pneumonia: implications for disease outcome. Thorax 2004; 59: 960965.
  • 14
    Rosón B, Carratala J, Fernandez-Sabe N et al. Causes and factors associated with early failure in hospitalized patients with community-acquired pneumonia. Arch Intern Med 2004; 164: 502508.
  • 15
    Menéndez R, Torres A, Rodríguez de Castro F et al. Reaching stability in community-acquired pneumonia: the effects of the severity of disease, treatment, and the characteristics of patients. Clin Infect Dis 2004; 39: 17831790.
  • 16
    Fine MJ, Auble TE, Yealy DM et al. A prediction rule to identify low-risk patients with community acquired pneumonia. N Engl J Med 1997; 336: 243250.
  • 17
    Lim WS, Van Der Eerden MM, Laing R et al. Defining community acquired pneumonia severity on presentation to hospital: an international derivation and validation study. Thorax 2003; 58: 377382.
  • 18
    Knaus WA, Draper EA, Wagner DP et al. APACHE II: a severity of disease classification system. Crit Care Med 1985; 13: 818829.
  • 19
    Angus DC, Marrie TJ, Obrosky DS et al. Severe community-acquired pneumonia: use of intensive care services and evaluation of American and British Thoracic Society diagnostic criteria. Am J Respir Crit Care Med 2002; 166: 717723.
  • 20
    Oosterheert JJ, Bonten MJ, Hak E et al. Severe community-acquired pneumonia: what's in a name? Curr Opin Infect Dis 2003; 16: 153159.
  • 21
    Chow AW, Hall CB, Klein JO et al. General guidelines for the evaluation of new anti-infective drugs for the treatment of respiratory tract infections. Clin Infect Dis 1992; 15 (suppl 1): s62s88.
  • 22
    Official Statement of the American Thoracic Society. Guidelines for the management of adults with community-acquired pneumonia. Am J Resp Crit Care Med 2001; 163: 17301754.
  • 23
    Weingarten SR, Riedinger MS, Varis G et al. Identification of low-risk hospitalized patients with pneumonia. Implications for early conversion to oral antimicrobial therapy. Chest 1994; 105: 11091115.
  • 24
    Woodhead MA, Macfarlane JT, American Thoracic Society. Comparative clinical and laboratory features of legionella with pneumococcal and mycoplasma pneumonias. Br J Dis Chest 1987; 81: 133139.
  • 25
    Stout JE, Yu VL. Legionellosis. N Engl J Med 1997; 337: 682687.
  • 26
    Kasteren ME, Wijnands WJ, Stobberingh EE et al. Optimization of the antibiotics policy in The Netherlands. II. SWAB guidelines for the antimicrobial therapy of pneumonia in patients at home and as nosocomial infections. The Netherlands Antibiotic Policy Foundation. Ned Tijdschr Geneeskd 1998; 142: 952956.
  • 27
    Hosmer DW, Lemeshow S. Applied logistic regression. New York: Wiley, 1998; 135175.
  • 28
    Hanley JA, McNeill BJ. The meaning and use of the area under the receiver operating characteristic curve (ROC). Radiology 1982; 143: 2936.
  • 29
    Hak E, Wei F, Nordin J et al. Development and validation of a clinical prediction rule for hospitalisation due to pneumonia or influenza or death during influenza epidemics among community-dwelling elderly persons. J Infect Dis 2004; 189: 450458.
  • 30
    Mortensen EM, Coley CM, Singer DE et al. Causes of death for patients with community-acquired pneumonia: results from the Pneumonia Patient Outcomes Research Team cohort study. Arch Intern Med 2002; 162: 10591064.
  • 31
    Ruiz M, Ewig S, Torres A et al. Severe community-acquired pneumonia. Risk factors and follow-up epidemiology. Am J Respir Crit Care Med 1999; 160: 923929.
  • 32
    De Roux A, Marcos MA, Garcia E et al. Viral community-acquired pneumonia in nonimmunocompromised adults. Chest 2004; 125: 13431351.
  • 33
    Tuuminen T, Palomaki P, Paavonen J. The use of serologic tests for the diagnosis of chlamydial infections. J Microbiol Meth 2000; 45: 265279.
  • 34
    Rhew DC, Tu GS, Ofman J et al. Early switch and early discharge strategies in patients with community- acquired pneumonia: a meta-analysis. Arch Intern Med 2001; 161: 722727.
  • 35
    Ortqvist A, Kalin M, Lejdeborn L et al. Diagnostic fiberoptic bronchoscopy and protected brush culture in patients with community-acquired pneumonia. Chest 1990; 97: 576582.
  • 36
    Roy S, Knox K, Segal S et al. MBL genotype and risk of invasive pneumococcal disease: a case-control study. Lancet 2002; 359: 15691573.
  • 37
    Waterer GW, Quasney MW, Cantor RM et al. Septic shock and respiratory failure in community-acquired pneumonia have different TNF polymorphism associations. Am J Respir Care Med 2001; 163: 15991604.
  • 38
    Waterer GWEI, Bahlawan L, Quasney MW et al. Heat shock protein 70–2+1267 AA homozygotes have an increased risk of septic shock in adults with community-acquired pneumonia. Crit Care Med 2003; 31: 13671372.